Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study

被引:7
|
作者
Verstockt, Bram [1 ,2 ,3 ,5 ]
Pouillon, Lieven [1 ]
Ballaux, Florence [4 ]
Jorissen, Celine [1 ,2 ]
Hoefkens, Eveline [1 ]
Lembrechts, Nikki [1 ]
Bossuyt, Peter [1 ]
机构
[1] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[2] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Chron Dis & Metab, Translat Res Gastrointestinal Disorders, Leuven, Belgium
[4] Imelda Gen Hosp, Dept Pathol, Bonheiden, Belgium
[5] Univ Hosp Leuven, Herestr 49, B-3000 Leuven, Belgium
来源
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷 / 07期
关键词
Ulcerative colitis; PRO; patient-reported outcomes disability; endpoint; histo-endoscopic remission; MAINTENANCE THERAPY; DOUBLE-BLIND; IBD-DISK; INDUCTION; TRIALS; TOOL;
D O I
10.1093/ecco-jcc/jjad015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims Treating beyond endoscopic remission, aiming for histological remission, is an emerging target in ulcerative colitis [UC]. Patient-reported outcome measurements [PROMs] become increasingly important, but their association with histology is unclear. Methods Multiple PROMs were prospectively collected in UC patients undergoing colonoscopy. Mayo endoscopic sub-score [MES] and ulcerative colitis endoscopic index of severity [UCEIS] were determined, as well as the Nancy histological index [NHI] of the most affected area. Endoscopic remission was defined as MES and UCEIS 0, histological remission as NHI 0, and histo-endoscopic mucosal remission [HEMR] as a combination of both. Results A total of 109 assessments were collected in 80 patients with endoscopic and HEMR remission rates of 24.8% and 16.5%, respectively. Patients with HEMR had a significantly lower overall inflammatory bowel disease [IBD] disability [p <0.001] and disease activity score [p <0.001] as compared with patients without. In line, NHI correlated with the overall IBD-disk [r = 0.36, p <0.001] and simple clinical colitis activity index [SCCAI] score [r = 0.44, p <0.001]. Many individual components of both differed significantly between patients with and without HEMR. Although the overall accuracy of the IBD-disk [0.78] or SCCAI score [0.83] for HEMR is lower [p <0.005] than the MES or UCEIS [0.95], a cumulative IBD-disk score >35.5 and an SSCAI score >3.5 have a high negative predictive value [98.6% and 100.0%, respectively] to exclude HEMR. Conclusion Histo-endoscopic inactive disease is associated with reduced IBD disability, but not with complete absence thereof. PROMs for disability and clinical disease activity cannot fully replace histo-endoscopic findings, and should be considered complementary in patient-centred endpoint discussions. Nevertheless, PROMs have a high negative predictive value to rule out HEMR.
引用
收藏
页码:1046 / 1054
页数:9
相关论文
共 50 条
  • [21] Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis
    Ma, Christopher
    Sandborn, William J.
    D'Haens, Geert R.
    Zou, Guangyong
    Stitt, Larry W.
    Singh, Siddharth
    Ananthakrishnan, Ashwin N.
    Dulai, Parambir S.
    Khanna, Reena
    Jairath, Vipul
    Feagan, Brian G.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (08) : 1760 - +
  • [22] Patient-Reported Racial and Ethnic Disparities in Patients With Ulcerative Colitis: Results From the National Health and Wellness Survey
    Burbage, Sabree C.
    Krupsky, Kathryn L.
    Cambron-Mellott, M. Janelle
    Way, Nate
    Patel, Aarti A.
    Liu, Julia J.
    [J]. CROHNS & COLITIS 360, 2024, 6 (04)
  • [23] Golimumab improves patient-reported work productivity and activity impairment in patients with ulcerative colitis: Interim results from a noninterventional trial in Germany
    Teich, N.
    Gruemmer, H.
    Joergensen, E.
    Liceni, T.
    Holtkamp-Endemann, F.
    Cornillie, F.
    Hohenberger, S.
    Fischer, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S388 - S388
  • [24] Comment on an Optimized Patient-reported Ulcerative Colitis Disease Activity Measure Derived from the Mayo Score and the Simple Clinical Colitis Activity Index
    Walmsley, Russell S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : E25 - E26
  • [25] Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis
    Dulai, Parambir S.
    Singh, Siddharth
    Jairath, Vipul
    Ma, Christopher
    Narula, Neeraj
    Casteele, Niels Vande
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    D'Haens, Geert
    Feagan, Brian G.
    Sandborn, William J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (04) : 435 - 445
  • [26] Tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes
    Panes, J.
    Su, C.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Mamolo, C.
    Healey, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S51 - S51
  • [27] Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitis
    Colombel, J. -F.
    Keir, M.
    Scherl, A.
    Zhao, R.
    de Hertogh, G.
    Faubion, W.
    Lu, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S61 - S61
  • [28] Development of the Ulcerative Colitis Patient-Reported Outcomes (UC-PRO) Questionnaire
    Higgins, Peter D.
    Harding, Gale
    Patrick, Donald L.
    Revicki, Dennis A.
    Globe, Gary
    Viswanathan, Hema N.
    Trease, Sarah
    Fitzgerald, Kristina
    Borie, Dominique C.
    Leidy, Nancy K.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S768 - S768
  • [29] Discrepancies Between Patient-Reported Outcomes, Endoscopic and Histologic Appearance in Ulcerative Colitis
    Colombel, Jean-Frederic
    Keir, Mary
    Scherl, Alexis
    Zhao, Rui
    De Hertogh, Gert
    Faubion, William
    Lu, Timothy
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S992 - S992
  • [30] Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
    Dubinsky, M. C.
    Bressler, B.
    Armuzzi, A.
    Salese, L.
    DiBonaventura, M.
    Maller, E.
    Fan, H.
    Woodworth, D. A.
    Su, C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S462 - S463